Biogen
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1978-01-01
- Employees
- 7.5K
- Market Cap
- $29.6B
- Website
- https://www.biogen.com
- Introduction
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
La-Z-Boy and Winnebago Highlighted as Zacks Bull and Bear of the Day
La-Z-Boy (LZB) is highlighted as a strong buy with a Zacks Rank #1, showcasing resilience and strategic growth despite market challenges. Winnebago Industries (WGO) is a strong sell due to disappointing earnings and lower estimates. Eli Lilly (LLY) shows promise with its drug tirzepatide for sleep apnea and obesity, alongside a robust pipeline. Novo Nordisk (NVO) and Biogen (BIIB) are also noted for their contributions to the pharmaceutical sector.
Is Eli Lilly (LLY) a Buy on Tirzepatide Success in Sleep Apnea?
Eli Lilly's tirzepatide, marketed as Mounjaro for diabetes and Zepbound for obesity, shows promise in treating sleep apnea, with recent studies indicating significant reductions in sleep apnea events. Lilly seeks FDA approval for this expanded use, potentially boosting sales. The company's strong pipeline, including Alzheimer's drug donanemab, and robust financial performance, driven by high demand for its drugs, position it well for future growth.
FDA approves donanemab, Eli Lilly’s treatment for early Alzheimer’s disease
The FDA approved donanemab, a monoclonal antibody by Eli Lilly, to slow early Alzheimer's progression. Priced at $695 per vial, it targets amyloid plaque. Clinical trials showed a 35% lower disease progression risk over 18 months compared to placebo, with rare serious side effects. It's not a cure but extends independence. Lilly emphasizes early detection's importance, as Alzheimer's affects millions, with projections to nearly 14 million by 2060. The Alzheimer’s Association welcomes this as progress, offering more treatment options.
FDA advisers strongly back new Alzheimer’s drug, despite risks and limitations
FDA advisers unanimously recommend approving Alzheimer’s drug donanemab, highlighting its effectiveness in early stages and benefits outweighing risks. It could allow halting treatment if amyloid plaques are removed, potentially within a year. Concerns include brain swelling/bleeding risks, especially for APOE4 gene carriers, but advocates stress the need for aggressive treatment options.
Biogen, looking to diversify, acquires immune drugmaker Human Immunology Biosciences
Biogen acquires Human Immunology Biosciences for $1.15B, potentially $650M more, to diversify its neurology-focused pipeline with felzartamab, a drug in Phase 2 for kidney conditions. This move aims to reduce pipeline risk and expand into immunology, aligning with CEO Viehbacher's strategy to revive growth.
Denali Therapeutics Reports First Quarter 2024 Financial
Denali Therapeutics reported Q1 2024 financials, highlighting progress in neurodegenerative and lysosomal storage disease treatments. Key updates include positive clinical data for tividenofusp alfa in MPS II, DNL343's Phase 2/3 ALS trial enrollment completion, and advancements in Parkinson’s and Alzheimer’s therapies. The company raised $500M in financing, focusing on BBB-crossing therapeutics.
Medicare Says It Expects To Spend $3.5 Billion In 2025 On Alzheimer’s Drug Leqembi, But This Is Unlikely
CMS estimates Medicare could spend $3.5 billion on Alzheimer's drug Leqembi by 2025, despite current low sales and safety concerns. Similar to Aduhelm's failure, Leqembi's uptake is slow, with modest cognitive benefits and safety risks. Medicare's projections may be overly optimistic, given the drug's limited market penetration and ongoing safety and efficacy concerns.
Biogen Is Suffering From Doubts About the Future
Biogen Inc. faces revenue decline and market skepticism due to competition, generic drug launches, and R&D challenges. Despite mixed Q4 2023 results and a 6.20% revenue drop, efforts to optimize costs and grow Skyclarys sales offer some hope. Rated 'market perform' for the next year.
Alzheimer’s trial brings at-risk patients hope for the future, but new doubts in the present
Tyson Haller, at risk for Alzheimer's due to family history, participates in the AHEAD 3-45 study testing lecanemab, a drug aiming to prevent Alzheimer's by targeting amyloid plaques. Despite modest success in slowing disease progression, challenges remain, including high costs and side effects. The study represents hope for early intervention, with ongoing trials and debates on diagnosis and treatment efficacy.
Biotechnology Market Size to Reach USD 5.68 Trillion by 2033
The global biotechnology market, valued at USD 1.54 Trillion in 2023, is projected to reach USD 5.68 Trillion by 2033, growing at a CAGR of 13.95%. Growth is driven by government support, personalized medicine, COVID-19 vaccine development, agricultural biotech applications, and advancements in gene editing and synthetic biology. North America leads the market, while Asia Pacific is expected to grow the fastest.
© Copyright 2025. All Rights Reserved by MedPath